Presentation is loading. Please wait.

Presentation is loading. Please wait.

US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL by Farhad Ravandi, Megan.

Published byΠάνδαρος Γεννάδιος Modified over 5 years ago

Similar presentations

Presentation on theme: "US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL by Farhad Ravandi, Megan."— Presentation transcript:

1 US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL by Farhad Ravandi, Megan Othus, Susan M. O'Brien, Stephen J. Forman, Chul S. Ha, Jeffrey Y. C. Wong, Martin S. Tallman, Elisabeth Paietta, Janis Racevskis, Geoffrey L. Uy, Mary Horowitz, Naoko Takebe, Richard Little, Uma Borate, Partow Kebriaei, Laura Kingsbury, Hagop M. Kantarjian, Jerald P. Radich, Harry P. Erba, and Frederick R. Appelbaum BloodAdv Volume 1(3): December 27, 2016 ©2016 by American Society of Hematology

2 Farhad Ravandi et al. Blood Adv 2016;1:250-259
©2016 by American Society of Hematology

3 Treatment regimen. Treatment regimen. (A) Original regimen. Dasatinib was administered at 100 mg daily for the first 14 days of each of the consolidation cycles. (B) Modified regimen after amendment. The dasatinib dose was modified to 70 mg orally daily continuously from course 2 onward during the consolidation cycles. MTX, methotrexate. Farhad Ravandi et al. Blood Adv 2016;1: ©2016 by American Society of Hematology

4 Patient disposition and response.
Patient disposition and response. SCT, stem cell transplant. Farhad Ravandi et al. Blood Adv 2016;1: ©2016 by American Society of Hematology

5 Survival outcomes. Survival outcomes. (A) Event-free survival for the whole cohort. (B) Relapse-free survival for the whole cohort. (C) Overall survival for the whole cohort. (D) Relapse-free survival in patients with no protocol transplant in first remission. (E) Overall survival in patients with no protocol transplant in first remission. Farhad Ravandi et al. Blood Adv 2016;1: ©2016 by American Society of Hematology

6 Outcomes with protocol-specified HCT
Outcomes with protocol-specified HCT. (A) Relapse-free survival after protocol-specified HCT. (B) Overall survival after protocol-specified HCT. (C) Relapse free survival; landmark analysis HCT versus no HCT, in favor of HCT; hazard ratio (HR) 0.42, 95% CI ( ). Outcomes with protocol-specified HCT. (A) Relapse-free survival after protocol-specified HCT. (B) Overall survival after protocol-specified HCT. (C) Relapse free survival; landmark analysis HCT versus no HCT, in favor of HCT; hazard ratio (HR) 0.42, 95% CI ( ). (D) Overall survival; landmark analysis HCT versus no HCT, in favor of HCT; HR 0.35, 95% CI ( ). Farhad Ravandi et al. Blood Adv 2016;1: ©2016 by American Society of Hematology

7 Toxicity. Toxicity. (A) Grades 3 and 4 adverse events during induction/consolidation cycles. (B) Adverse events during maintenance cycles. GI, gastrointestinal; LFT, liver function tests; NV, nausea and vomiting. Farhad Ravandi et al. Blood Adv 2016;1: ©2016 by American Society of Hematology

Download ppt "US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL by Farhad Ravandi, Megan."

Similar presentations

A disease risk index for patients undergoing allogeneic stem cell transplantation by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T. Ho,

A disease risk index for patients undergoing allogeneic stem cell transplantation by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T. Ho,
Long-term Outcome after hyper-CVAD and Imatinib for De Novo or Minimally Treated Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph-ALL)

Long-term Outcome after hyper-CVAD and Imatinib for De Novo or Minimally Treated Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph-ALL)
UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
1 Stone RM et al. Proc ASH 2015;Abstract 6.

1 Stone RM et al. Proc ASH 2015;Abstract 6.
Shah N et al. Proc ASH 2010;Abstract 206.

Shah N et al. Proc ASH 2010;Abstract 206.
Maury S et al. Proc ASH 2015;Abstract 1.

Maury S et al. Proc ASH 2015;Abstract 1.
Gajria D et al. Proc SABCS 2010;Abstract P

Gajria D et al. Proc SABCS 2010;Abstract P
Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al

Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al
Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.
Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation by Christopher Bredeson, Jennifer.

Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation by Christopher Bredeson, Jennifer.
Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,
Sirolimus in Combination with Cyclosporine or Tacrolimus Plus Methotrexate for Prevention of Graft-versus-Host Disease following Hematopoietic Cell Transplantation.

Sirolimus in Combination with Cyclosporine or Tacrolimus Plus Methotrexate for Prevention of Graft-versus-Host Disease following Hematopoietic Cell Transplantation.
Erba HP et al. Blood 2008;112: Abstract 558

Erba HP et al. Blood 2008;112: Abstract 558
Megan Othus, Frederick R. Appelbaum, Stephen H. Petersdorf, Kenneth J

Megan Othus, Frederick R. Appelbaum, Stephen H. Petersdorf, Kenneth J
Cortes JE et al. Proc ASCO 2010;Abstract 6502.

Cortes JE et al. Proc ASCO 2010;Abstract 6502.
Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma by Nicolaus Kröger,

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma by Nicolaus Kröger,
Gupta V, Tallman MS, Weisdorf DJ

Gupta V, Tallman MS, Weisdorf DJ
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.

Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.
The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.

Similar presentations

Ads by Google